The new federal hemp framework prohibits cannabinoids that are “unnatural or synthesized” — cannabinoids that do not naturally occur in the hemp plant. For B2B buyers, ingredient procurement teams, and formulators, this prohibition is significant because it affects a category of hemp-derived ingredients that has been widely available in the commercial market and that many brands have built products around.
But “synthetic cannabinoid” is a term that carries more nuance than its regulatory use suggests. Understanding the precise definition — what it includes, what it doesn’t, and how it’s verified in a supply chain context — is essential for B2B buyers making sourcing decisions in 2026.
The Regulatory Definition: Cannabinoids That Don’t Naturally Occur in Hemp
The federal hemp framework uses a functional definition: a synthetic cannabinoid is a cannabinoid that does not naturally occur in the hemp plant. This is not a manufacturing process definition — it is not about whether a chemical was made in a laboratory versus extracted from a plant. It is about whether the resulting molecule is one that exists naturally in Cannabis sativa L.
This distinction is critical for understanding which cannabinoids are and aren’t affected:
Cannabinoids that naturally occur in hemp (generally not prohibited as synthetic):
- CBD (cannabidiol)
- CBG (cannabigerol)
- CBN (cannabinol)
- CBC (cannabichromene)
- Delta-9 THC (in trace amounts)
- Delta-8 THC (in trace, naturally occurring amounts in the hemp plant)
- THCV, CBDV, CBDA, CBGA, and other naturally occurring minor cannabinoids
Cannabinoids that are synthetic or unnatural (prohibited under the new standard):
- THC-O-acetate (THC-O): does not naturally occur in hemp, created only through chemical synthesis from hemp-derived cannabinoids
- THCP (tetrahydrocannabiphorol) in concentrated form: while trace THCP has been identified in cannabis, the concentrated versions sold commercially are synthetically produced
- HHC (hexahydrocannabinol): produced through chemical hydrogenation of THC, not naturally occurring in hemp in commercial quantities
- Delta-10 THC in commercial concentrations: while trace delta-10 may occur naturally, commercial delta-10 is virtually always produced through chemical isomerization
- Any novel cannabinoid analogue or derivative not documented as a natural hemp constituent
The Delta-8 Question: Where It Gets Complicated
Delta-8 THC occupies the most contested space in the synthetic cannabinoid question — because delta-8 does occur naturally in hemp, but virtually all commercially available delta-8 is not directly extracted from hemp. It is produced through chemical isomerization of CBD using acid catalysts.
The regulatory status of isomerized delta-8 has been a subject of significant debate. The core question: is delta-8 THC produced through chemical conversion of CBD a “synthetic” cannabinoid if the resulting molecule is one that naturally occurs in hemp?
The current federal position — and the position underlying the ONDCP strategy’s naming of delta-8 as an enforcement target — is that commercially produced delta-8 (isomerized from CBD rather than directly extracted from hemp) is unnatural in the sense prohibited by the new standard. The process by which it is made places it in the synthetic category even though the molecule itself occurs naturally.
For B2B buyers: any ingredient described as delta-8 THC distillate, delta-8 THC concentrate, or delta-8-based formulation is almost certainly produced through chemical conversion and should be treated as a prohibited cannabinoid under the new federal standard.
Why the Distinction Matters for B2B Ingredient Sourcing
For B2B ingredient buyers, the synthetic cannabinoid prohibition creates specific due diligence requirements:
COA identification is not sufficient alone. A COA that shows “delta-8 THC: 0mg” or “THC-O: ND” demonstrates that those cannabinoids are not present at detectable levels — but it doesn’t prove the absence of other synthetic or novel cannabinoids unless the lab panel specifically tests for them.
Full cannabinoid panel testing is required. To verify that an ingredient is free of synthetic cannabinoids, the COA must include a comprehensive cannabinoid panel that specifically tests for THC-O, HHC, delta-10, and other synthetic cannabinoid analogues — not just the standard hemp panel (delta-9, THCA, CBD, CBG, CBN, CBC).
Supplier disclosure is necessary but not sufficient. A supplier’s representation that their ingredients contain no synthetic cannabinoids should be part of your supply agreement — but it needs to be backed by COA-level verification on a lot-specific basis.
Process documentation matters. For cannabinoids in the gray zone (like delta-8), knowing the manufacturing process — how the cannabinoid was produced — is necessary to evaluate compliance status. Ask your supplier to document the extraction and production process for any hemp-derived cannabinoid ingredient that isn’t straight CBD isolate or distillate.
What to Ask Your Supplier
To verify that your hemp ingredient supply chain is free of prohibited synthetic cannabinoids, your supplier needs to be able to answer these questions affirmatively:
- Does your COA include testing for THC-O, HHC, delta-10 THC, and other synthetic cannabinoid analogues?
- Can you document the production process for all cannabinoid ingredients, including whether any involve chemical conversion (isomerization, hydrogenation, acetylation)?
- Does your supply agreement include a representation that no synthetic or unnatural cannabinoids are present in supplied ingredients?
- Are your cannabinoid ingredients directly extracted from hemp plant material, or produced through downstream chemical conversion of hemp-derived precursors?
Suppliers who can’t answer these questions with documentation are not suppliers you can source from with confidence under the new federal standard.
LGH Perspective
At Low Gravity Hemp, our ingredient supply chain is built entirely around naturally occurring cannabinoids directly derived from hemp plant material — not from chemical conversion or synthesis. Our full-panel COAs from ISO 17025-accredited labs include testing for synthetic cannabinoid analogues, and our supply agreements include explicit representations that no prohibited synthetic cannabinoids are present. When our customers need to represent to their retail buyers, compliance officers, or regulators that their ingredients are free of synthetic cannabinoids, we provide the documentation to back that claim.
Final Thoughts
The synthetic cannabinoid prohibition in the 2026 federal hemp framework is substantive, not symbolic. It eliminates from the legal hemp market an entire category of products that have been widely sold and that some hemp brands have built significant revenue around. For B2B ingredient buyers, the prohibition creates specific due diligence obligations that go beyond the total THC calculation — you need to know not just how much THC is in your ingredient, but what that THC is and how it got there.
Natural cannabinoid profiles, documented extraction processes, and full-panel COA testing are the tools that give you confidence in your compliance status on the synthetic cannabinoid question.
Want to verify that your ingredient supply chain is free of prohibited synthetic cannabinoids? Contact Low Gravity Hemp to discuss our full-panel testing protocols and natural cannabinoid supply chain documentation.
